TRAF2 is an NF-κB activating oncogene in epithelial cancers
Zhou, Alicia Y.
O’Connell, Joyce T.
MetadataShow full item record
CitationShen, Rhine R., Alicia Y. Zhou, Eejung Kim, Joyce T. O’Connell, Daniel Hagerstrand, Rameen Beroukhim, and William C. Hahn. 2014. “TRAF2 is an NF-κB activating oncogene in epithelial cancers.” Oncogene 34 (2): 209-216. doi:10.1038/onc.2013.543. http://dx.doi.org/10.1038/onc.2013.543.
AbstractAberrant NF-κB activation is frequently observed in human cancers. Genome characterization efforts have identified genetic alterations in multiple components of the NF-κB pathway, some of which have been shown to be essential for cancer initiation and tumor maintenance. Here using patient tumors and cancer cell lines, we identify the NF-κB regulator, TRAF2 as an oncogene that is recurrently amplified and rearranged in 15% of human epithelial cancers. Suppression of TRAF2 in cancer cells harboring TRAF2 copy number gain inhibits proliferation, NF-κB activation, anchorage-independent growth and tumorigenesis. Cancer cells that are dependent on TRAF2 also require NF-κB for survival. The phosphorylation of TRAF2 at serine 11 is essential for the survival of cancer cells harboring TRAF2 amplification. Together these observations identify TRAF2 as a frequently amplified oncogene.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:17820652